Effect of Pamidronate on Osteoporosis in Patients with β-Thalassemia Major

Journal Title: Iranian Journal of Blood and Cancer - Year 2014, Vol 6, Issue 3

Abstract

Background: β-thalassemia major is a hereditary life threatening anemia which requires regular blood transfusion. Clinical symptoms of the disease are growth retardation, pallor, jaundice and skeletal alternations. The variety of bone disease in thalassemia major is manifested by diffuse bone pain or deformity, spontaneous and pathologic fractures and osteopenia or osteoporosis. This study aimed to evaluate the effect of Pamidronate on beta thalassemia major induced osteoporosis. Patients and Methods: This cross sectional study was conducted on 20 patients with β-thalassemia major with osteoporosis. Patients received Pamidronate injections (30 mg in equal intervals of one month) for one year. At the beginning and the end of study period (after twelve months of treatment) patients’ BMD and Z score of lumbar spine and Hip were determined. Results: The mean baseline BMD of lumbar spine and hip among patients were 097/0±720/0(gr/cm²) and 083/0±684/0 (gr/cm²) respectively which at the end of the study these numbers reached to 100/0±783/0(gr/cm²) (p<0.001) and 097/0±713/0(gr/cm²) (p=0.015) respectively. The mean baseline Z score of lumbar spine and hip for patients were /0±98/2-956 and 727/0±96/1- before treatment (one full year of treatment) that reached 886/0±44/2- (p=0.001) and 856 /0±47/1- (p=0.003) respectively. The baseline alkaline phosphatase was 94/89±85/385 µg/dl and after treatment this value decreased to 66/113±95/251µg/dl (p<0.001). Conclusion: The Pamidronate is effective in increasing the bone mineral density and improving the osteoporosis condition in patients with β-thalassemia major. Keywords: Osteoporosis, BMD (Bone Mineral Density), β-thalassemia major, Pamidronate.

Authors and Affiliations

Majid Naderi, Zahra Zakeri, Akbar Dorgalaleh, Shaban Alizadeh, Shadi Tabibian, Taregh Bamedi

Keywords

Related Articles

Relation between the Short Term Health Related Quality of Life and Various Types of Medical Treatment in Patients with Idiopathic Chronic Thrombocytopenia

Background:Chronic Idiopathic Thrombocytopenic Purpura (ITP) is an autoimmune disorder characterized by a low platelet count due to reduced production and higher destruction of the platelets. Therapy is aimed at increasi...

Frequency of Torque Teno Mini Virus in Hepatitis B and C Patients and Healthy Blood Donors in Isfahan, Iran

Background: Recently, some new viruses have been identified for their association with hepatitis which Torque Teno Mini Virus being among them. The aim of this study was to determine the frequency of Torque Teno Mini Vir...

Expression Analysis of Foxo3a Gene in Pediatric Acute Lymphoblastic Leukemia in Southern Iranian Population

Background: Acute lymphoblastic leukemia (ALL), the most common childhood cancer with a peak incidence in children from 2-5 years old, might be associated with poor prognosis and resistance to therapy in specific cytogen...

Heterozygote Hemoglobin J Iran in Combination with Hemoglobin H Disease

This is a report concerning a concurrent case of hemoglobin J Iran (Hb J Iran) and Hemoglobin H (Hb H) disease in an Iranian woman. The patient was coincidentally found during the course of routine pre-marital genetic co...

Download PDF file
  • EP ID EP364651
  • DOI -
  • Views 91
  • Downloads 0

How To Cite

Majid Naderi, Zahra Zakeri, Akbar Dorgalaleh, Shaban Alizadeh, Shadi Tabibian, Taregh Bamedi (2014). Effect of Pamidronate on Osteoporosis in Patients with β-Thalassemia Major. Iranian Journal of Blood and Cancer, 6(3), 149-153. https://europub.co.uk/articles/-A-364651